United States, May 8 -- The U.S. Food and Drug Administration issued a final guidance for industry, Postapproval Pregnancy Safety Studies, with recommendations on different methodologies that can be used in the postapproval setting to study the safety of drugs and biological products when used during pregnancy. Many pregnant women may benefit from medications to treat ongoing or new health conditions, but often there is limited or no human data available about how these products affect pregnancy at the time they are approved. Because of this, collecting safety information after approval is important to better understand potential risks to both the pregnant patient and the developing fetus. These studies often require input from experts in a...